From thalassemia to sickle cell: Bone marrow transplants as a ‘reset’ for genetic blood disorders

For decades, the term Bone Marrow Transplant (BMT) has been synonymous with the battle against leukaemia and lymphoma. However, as medical science enters a new era, this life-saving procedure is shedding its cancer-only label.

In India, where the burden of hemoglobinopathies is immense with over 10,000 children born annually with Thalassemia major, BMT is emerging as a critical "reset button" for those with defective genetic blueprints.

According to Dr. (Maj) Ravi Shankar, Consultant – Paediatric Haemato-Oncology and BMT at Yatharth Hospital (Model Town) advances in medical science have expanded the role of BMT far beyond conditions like leukaemia and lymphoma. Today, it is being used to treat genetic and immune-related blood disorders such as thalassemia and sickle cell disease, which affect a large number of patients in India.

More from Health

“In such cases, the problem lies not with cancer but with the bone marrow itself,” he explained. “A transplant effectively replaces a faulty system with a healthy one, acting as a reset for both blood production and the immune system.”

Experts underline that early diagnosis remains critical. Detecting genetic disorders through screening at an early stage can prevent irreversible organ damage and significantly improve outcomes. However, awareness alone is not enough, as access to timely treatment remains a challenge.

In India, BMT facilities are largely concentrated in major urban centres, limiting access for patients in smaller towns. The cost of the procedure—often running into tens of lakhs of rupees—poses a significant barrier for most families. Additionally, finding a compatible donor remains a major hurdle due to underdeveloped donor registries.

Despite these challenges, advancements in treatment are offering new hope. Doctors are increasingly using less intensive pre-transplant conditioning methods, making the procedure safer and more accessible to a wider group of patients. Emerging technologies such as gene-edited stem cells are also beginning to expand treatment possibilities, particularly for non-cancer patients.

The focus now, experts say, must be on bridging the gap between medical innovation and patient access, ensuring that these life-saving treatments reach those who need them most.